公开(公告)号：US20240216489A1

公开(公告)日：2024-07-04

申请号：US18554641

申请日：2022-04-20

Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Inventor： Valder R. Arruda

IPC: A61K39/00 ,  A61K38/37 ,  A61P37/06

CPC classification number: A61K39/001 ,  A61K38/37 ,  A61P37/06 ,  A61K2039/5256

Abstract: Methods for immune tolerance induction and eradication of anti-drug antibodies to therapeutic Factor VIII are disclosed.

公开(公告)号：US20240000830A1

公开(公告)日：2024-01-04

申请号：US18330319

申请日：2023-06-06

Applicant: onCour Pharma, Inc.

Inventor： Daniel R. GETTS

IPC: A61K31/78 ,  A61K9/00 ,  A61K39/00 ,  A61K39/39 ,  A61K31/01 ,  A61K31/74 ,  A61K31/765 ,  G01N33/68 ,  A61P35/00 ,  A61K9/14 ,  A61K31/00 ,  A61K9/16

CPC classification number: A61K31/78 ,  A61K9/0019 ,  A61K39/001 ,  A61K39/39 ,  A61K31/01 ,  A61K31/74 ,  A61K31/765 ,  G01N33/6893 ,  A61P35/00 ,  A61K9/14 ,  A61K39/0005 ,  A61K31/00 ,  A61K9/146 ,  A61K9/1647 ,  G01N2800/7095 ,  A61K2039/55555 ,  Y02A50/30

Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.

公开(公告)号：US11844827B2

公开(公告)日：2023-12-19

申请号：US17531897

申请日：2021-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Noga Or-Geva ,  Eran Ophir ,  Yaki Eidelstein ,  Rotem Gidron Budovsky

IPC: A61K39/00 ,  A61K35/17 ,  C12N5/078 ,  C12N5/0783 ,  A61P31/00 ,  A61P35/04 ,  A61K39/395 ,  C07K16/28 ,  A61K35/12

CPC classification number: A61K39/001 ,  A61K35/17 ,  A61K39/39566 ,  A61P31/00 ,  A61P35/04 ,  C07K16/2896 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0648 ,  A61K2035/122 ,  A61K2039/5158 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  Y02A50/30

Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US20230383254A1

公开(公告)日：2023-11-30

申请号：US18232437

申请日：2023-08-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Sivan KAGAN

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  C12N5/00

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K39/001 ,  C12N5/0087 ,  A61K2035/122

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20230323288A1

公开(公告)日：2023-10-12

申请号：US17993667

申请日：2022-11-23

Applicant: President and Fellows of Harvard College

Inventor： Torsten B. Meissner ,  Leonardo M.R. Ferreira ,  Jack L. Strominger ,  Chad A. Cowan

IPC: C12N15/86 ,  C12N5/0735 ,  C12N5/074 ,  C12N15/90 ,  A61K39/00

CPC classification number: C12N5/0606 ,  A61K39/001 ,  C12N5/0696 ,  C12N15/86 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/50 ,  C12N2501/599 ,  C12N2501/998 ,  C12N2510/00

Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.

公开(公告)号：US20230321224A1

公开(公告)日：2023-10-12

申请号：US18063610

申请日：2022-12-08

Applicant: Selecta Biosciences, Inc.

Inventor： Christopher Fraser ,  Takashi Kei Kishimoto ,  Roberto A. Maldonado

IPC: A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  A61K39/00 ,  A61K9/127 ,  A61K9/51 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y5/00 ,  A61K39/36 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K38/18

CPC classification number: A61K39/385 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  A61K39/001 ,  A61K39/0008 ,  A61K9/127 ,  A61K9/5146 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K39/00 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/5115 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K9/5153 ,  A61K38/1816 ,  A61K9/51 ,  G01N2333/70517 ,  G01N2333/70514 ,  G01N2333/7051 ,  A61K2039/5154 ,  A61K2039/577 ,  A61K2039/55511 ,  A61K2039/55555 ,  Y02A50/30 ,  A61K39/35

Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.

公开(公告)号：US11744889B2

公开(公告)日：2023-09-05

申请号：US16067812

申请日：2017-01-05

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Louis D. Falo, Jr. ,  Adriana Teresita Larregina De Morelli

IPC: A61K39/35 ,  A61K39/39 ,  A61K9/00 ,  A61K38/19 ,  A61K39/00 ,  A61K38/04

CPC classification number: A61K39/35 ,  A61K9/0021 ,  A61K38/046 ,  A61K38/19 ,  A61K39/001 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/555 ,  A61K2039/577 ,  A61K38/19 ,  A61K2300/00 ,  A61K38/046 ,  A61K2300/00

Abstract: Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

公开(公告)号：US20230149523A1

公开(公告)日：2023-05-18

申请号：US17754809

申请日：2020-10-13

Applicant: FIGENE, LLC

Inventor： Thomas ICHIM

IPC: A61K39/00 ,  C12N5/077 ,  C12N5/0784 ,  A61K35/33 ,  A61K35/28 ,  A61K38/20

CPC classification number: A61K39/0008 ,  A61K35/28 ,  A61K35/33 ,  A61K38/2013 ,  A61K39/001 ,  C12N5/0639 ,  C12N5/0656 ,  C12N2501/052

Abstract: The disclosure provides means of treating autoimmunity through reprogramming of antigen presenting cells in an individual in need of treatment through administration of fibroblasts and/or derivatives of fibroblasts. In one embodiment, fibroblasts are administered in an allogeneic manner subsequent to modification which endows fibroblast ability to alter antigen presenting cells in a manner which supports the generation of immunological tolerance as opposed to immunological rejection. In one embodiment, fibroblasts are utilized to decrease costimulatory molecule expression on antigen presenting cells, in order to allow for production of antigen-specific immunological tolerance promoting cells.

公开(公告)号：US20190192653A1

公开(公告)日：2019-06-27

申请号：US16053839

申请日：2018-08-03

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang

IPC: A61K39/39 ,  A61K39/38 ,  C12N15/88 ,  A61K39/00 ,  A61K39/35

CPC classification number: A61K39/39 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/35 ,  A61K39/38 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/572 ,  C12N15/88

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of molecules for tolerizing cellular systems.

公开(公告)号：US20190192561A1

公开(公告)日：2019-06-27

申请号：US16291477

申请日：2019-03-04

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Samuel Strober ,  Robert Lowsky

IPC: A61K35/12 ,  A61K35/22 ,  A61K35/28 ,  A61K39/395 ,  A61N5/10 ,  A61K38/13 ,  A61K31/573 ,  A61K31/436 ,  A61K45/06 ,  A61K41/00 ,  A61K38/19 ,  A61K35/14 ,  A61K35/17 ,  A61K39/00 ,  A61K31/365

CPC classification number: A61K35/12 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K35/14 ,  A61K35/17 ,  A61K35/22 ,  A61K35/28 ,  A61K38/13 ,  A61K38/193 ,  A61K39/001 ,  A61K39/395 ,  A61K39/39541 ,  A61K41/00 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/515 ,  A61K2039/54 ,  A61K2039/57 ,  A61N5/10 ,  A61K2300/00

Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.